Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

February 28, 2026

Conditions
Sepsis
Interventions
DEVICE

Hemofiltration membranes (the oXiris membrane® and the HF1400® membrane)

The PRISMAFLEX® or PRISMAX® control unit (pre- and post-dilution with a prescribed treatment dose \> 25 ml/kg/h) with regional citrate anticoagulation and a substitution solution by PHOXILLUM will be used regardless of the type of membrane used (the oXiris membrane and the HF 1400 membrane), also as part of routine care provided in the ICU.

Trial Locations (1)

33604

RECRUITING

Hopital Haut-Lévêque, Pessac

All Listed Sponsors
collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

University Hospital, Bordeaux

OTHER

NCT06440317 - Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane | Biotech Hunter | Biotech Hunter